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What's new? 
 
x Structured education for people with Type 1 diabetes is provided in many different 
formats, but very few randomized controlled trials examining the biomedical, 
psychological and cost-effectiveness of these formats have been performed. Course 
format may limit accessibility for some people. 
 
x Data from our randomized controlled trial shows that there were no major 
differences in outcomes between 5-week and 1-week Dose Adjustment for Normal 
Eating courses. 
 
x As participants highly valued both course formats, and some found it easier to 
attend one type than the other, we have been persuaded to provide both 5-week 
and 1-week courses in the future. 
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Abstract 
 
Aims To compare, in a randomized controlled non-inferiority trial, the outcomes of the 
traditional format for Dose Adjustment for Normal Eating structured education courses; that 
is, one delivered over 5 consecutive days (1-week course) with a variant of this format 
delivered 1 day a week for 5 consecutive weeks (5-week course). 
 
Methods Adults with Type 1 diabetes, from seven UK Dose Adjustment For Normal Eating 
training centres, were individually randomized, stratified by centre, to receive either a 1-
week or 5-week course. A qualitative study was embedded within the trial to explore 
ƉĂƚŝĞŶƚƐ ?ĞǆƉĞƌŝĞŶĐĞƐ ? 
 
Results In total, 213 patients were randomized and 160 completed the study procedures. In 
the per protocol analysis, the difference in HbA1c levels (95% CI) between the arms at 6 
months was 0.4 mmol/mol (-2.4, 3.1) or 0.03% (-0.22, 0.28) and -0.9 mmol/mol (-3.9, 2.2) or 
-0.08% (-0.36, 0.20) at 12 months. All confidence limits were within the non-inferiority 
margin of ±5.5 mmol/mol (0.5%) for ,ď ?ĐA? ?&ŽƌƚŚŽƐĞƉĂƚŝĞŶƚƐǁŝƚŚĂďĂƐĞůŝŶĞ,ď ?ĐŽĨA?
58 mmol/mŽů ?A? ? ? ?A? ?ƚŚĞŵĞĂŶĐŚĂŶŐĞ ? ? ?A?CI) in HbA1c was -2.2 mmol/mol (-4.0, -0.4) or 
-0.20% (-0.37, -0.04) at 6 months (P=0.016), and -2.0 mmol/mol (-4.1, 0.04) or -0.18% (-0.37 
to 0.004) at 12 months (P=0.055). Episodes of severe hypoglycaemia were decreased by 82% 
[relative risk 0.18 (95% CI 0.03 to 0.936); P=0.042], psychosocial outcomes improved 
significantly, and the difference between arms was not significant. Qualitative interviews 
showed that patients overwhelmingly favoured the format of course that they attended. 
 
Conclusions In summary, 5-week and 1-week Dose Adjustment for Normal Eating courses 
are equivalent in terms of biomedical and psychosocial outcomes, and we were persuaded 
that both course formats should be made available in routine care. 
 
(Clinical Trials Registry no: NCT01069393) 
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Introduction 
 
The Dose Adjustment for Normal Eating (DAFNE) course aims to improve HbA1c levels, 
whilst also reducing the occurrence of hypoglycaemia and increasing dietary freedom [1]. 
After the publication of the original trial, DAFNE training has been successfully rolled out to 
76 centres and self-management skills have been taught to >31 000 people with Type 1 
diabetes across the UK, as well as in centres abroad. Other centres have also adopted 
similar forms of structured education, albeit of varying duration, content and quality [2]. 
Ongoing internal and external quality assurance is an integral part of the DAFNE programme 
(and is listed as a required element of training in a Department of Health report [3]), but is 
rarely provided systematically by those running other courses. 
 
Despite national acknowledgement that structured skills training is a key element of 
diabetes care, access to it is not universal [4]. The possible limitations of providing DAFNE 
training only over 5 consecutive days from Monday to Friday has been raised [5]. It has been 
suggested that delivering courses on 1 day a week over a longer period may improve access 
for those in full-time work, whilst still improving glycaemic control, but a trial in which 
structured education was delivered for 2.5 days spread over 6 weeks failed to show 
improvement in biomedical outcomes [5]. Single centres running longer courses have 
reported similar outcomes to those of the DAFNE trial [6], but these findings are 
observational, uncontrolled and prone to bias. 
 
Different modes of course delivery may result in contrasting outcomes. It is conceivable, for 
instance, that a 1-week course may facilitate the incorporation of self-management skills via 
more intense bonding and peer support amongst course participants [7]. Alternatively, a 5-
week course may lead to better integration of self-management skills into everyday life, by 
enabling participants to practice key behaviours over longer periods between course dates. 
To evaluate the biomedical impact of an alternative mode of course delivery, and to explore 
ways to improve accessibility, we conducted a randomized controlled trial to compare 
outcomes after 5-day DAFNE courses delivered over 1 week (1-week course) with those 
from courses delivered over 1 day a week for 5 consecutive weeks (5-week course). 
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The DAFNE 5×1-day randomized controlled trial was designed to meet the following 
objectives: (1) to compare the effectiveness of DAFNE delivered over 1 week vs 5 weeks, in 
terms of both biomedical and quality-of-life outcomes; (2) to compare the cost-
effectiveness of the two formats; (3) to understand and interpret any differences and 
similarities in biomedical and psychological outcomes; (4) to ascertain patient preference 
for one format over the other (qualitative sub-study reported separately [8]; and (5) to 
provide recommendations for future delivery of DAFNE courses. 
 
 
Patients and methods 
 
The trial protocol has been reported previously [9]. Briefly, this multicentre randomized 
controlled trial involved seven UK DAFNE centres. Participants were recruited via waiting 
lists and, in some centres, by information evening meetings, and were informed of a pair of 
course dates (a 1-week or a 5-week course) for which they would need to be available. After 
obtaining written consent, participants were randomized to attend either a 1-week course 
(control arm delivered Monday to Friday) or a 5-week course (intervention arm delivered 1 
day a week over 5 consecutive weeks). To reduce bias, both course formats were delivered 
by the same two DAFNE educators in each centre. 
The content of the 5-week curriculum was identical to that of the standard 1-week DAFNE in 
terms of skills training and educational subject matter, with only minor adaptations [9]. A 
full economic analysis was undertaken, for which the methods are detailed in the protocol 
paper [9] and the results of which are reported in a separate paper [10]. Qualitative 
interviews were also undertaken with participants who attended the 5-week and 1-week 
courses, within 2 weeks of course completion, to establish their likes/dislikes of the course 
they had just attended and their views about whether, and why, future DAFNE courses 
should be offered in a 5-week and/or 1-week format [8]. 
 
The inclusion criteria were: diagnosis of Type 1 diabetes for at least 6 months; age 18 ?80 
years; not having previously attended a DAFNE course; HbA1c level <108 mmol/mol (12%); 
willingness to undertake intensive insulin therapy, with multiple self-monitoring tests of 
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blood glucose; willingness to undertake carbohydrate counting and insulin self-adjustment; 
and no strong views about attending a 1-week or 5-week course. The exclusion criteria 
were: severe diabetic complications; inability to communicate in English; strong preference 
for a 1-week or 5-week course; or inability to give informed consent. 
 
The sample size was calculated to test non-inferiority between the two different course 
delivery formats. Based on a non-inferiority margin in HbA1c level of 5.5 mmol/mol (0.5%), a 
standard deviation of 16.5 mmol/mol (1.5%), seven to eight participants per course, an 80% 
power at a one-sided 5% significance level and an intracluster correlation coefficient of 0.05, 
it was calculated that 150 participants were required to complete the trial. Assuming a 10% 
drop-out rate this meant randomizing 166 participants. Each centre was originally required 
to run four courses; that is, two pairs of 1-week and 5-week courses. As the trial progressed, 
however, the drop-out rate was higher than anticipated between the time of randomization 
and course attendance, so one centre ran an extra pair of courses. 
 
After baseline data collection, randomization of participants was performed individually 
using a random block size, stratified by centre and a blinded web-based remote 
randomization system. The allocation sequence was generated using a computer program 
RANDLOG (University of Southampton, Southampton, UK). 
 
Data on HbA1c levels, lipid profiles, weight, severe hypoglycaemic episodes, hospital 
admissions and psychosocial questionnaires were collected at baseline, and 6 and 12 
months after course completion. Based on findings from qualitative interviews after the 
courses a number of additional questions about self-management behaviours were built 
into a 12-month questionnaire, which also enquired about course format preference. The 
psychosocial questionnaires included measures to assess diabetes distress, mood and 
quality of life. HbA1c levels were measured at Diabetes Control and Complications Trial 
(DCCT)-aligned local laboratories (as per DCCT trial [11]). The primary outcome was change 
in HbA1c from levels at baseline to those at 6 and 12 months. Secondary outcomes were: 
ĐŚĂŶŐĞŝŶ,ď ?ĐǁŚĞƌĞƚŚĞďĂƐĞůŝŶĞ,ď ?ĐǁĂƐA? ? ?ŵŵŽů ?ŵŽů ? ? ? ?A? ?ƚŚŝƐǁĂƐďĞĐĂƵƐĞ
some patients choose to undergo DAFNE training in order to increase dietary freedom, or to 
decrease episodes of hypoglycaemia as opposed to reducing HbA1c level), number of 
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episodes of severe hypoglycaemia (defined as needing assistance of a third party to 
recover), changes in lipid profile /estimated glomerular filtration rate, and differences in 
psychosocial outcomes [9]. 
 
 
Statistical analysis 
 
We used a linear model of HbA1c at 12 months for the primary analysis, with baseline 
HbA1c as a covariate, using generalized estimating equations to control for clustering within 
courses. The intracluster correlation coefficient was estimated using the method of 
moments. A negative binomial model was used for the number of severe hypoglycaemic 
episodes during 12 months, which has more power than a dichotomy of having/not 
experiencing an episode, again using generalized estimating equations to account for 
clustering. A per-protocol analysis was the main analysis, as appropriate for a non-inferiority 
study [12]. An intent-to-treat analysis was also undertaken. When analysing psychosocial 
measures, missing data were imputed using the mean for domains for which > 50% of 
questions were answered. The full-analysis set for the intent-to-treat analysis included all 
patients for whom baseline data were collected. 
 
 
Ethical considerations 
 
Written informed consent was obtained from all participants. Ethical approval was obtained 
from the Derbyshire Research Ethics Committee (09/H0401/91). The study sponsor was 
Sheffield Teaching Hospitals NHS Foundation Trust and all components of the trial were 
approved by the local Research and Development departments of all participating centres. 
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Results 
 
Figure 1 shows the CONSORT diagram [14]. A total of 217 patients were assessed for 
eligibility, and 213 were randomized to either a 1-week or a 5-week course, between May 
2010 and May 2011. Of these, 180 patients commenced the course, and 160 completed 
study procedures (89%). The mean age of those randomized was 41.6 years and the mean 
duration of diabetes was 18.5 years. The remainder of the baseline summary statistics are 
summarized in Table 1, and baseline psychosocial questionnaire scores are shown in Table 
2. 
 
 
Outcomes: HbA1c (primary and secondary) 
 
Across the entire cohort, the improvements in HbA1c were small. For those patients with a 
baseline ,ď ?ĐŽĨA? ? ?ŵŵŽů ?ŵŽů ?A? ? ? ?A? ?ƚŚĞŵĞĂŶ ? ? ?A?/ ?ĐŚĂŶŐĞŝŶ,ď ?ĐǁĂs -2.2 
mmol/mol (-4.0, -0.4) or -0.2% (-0.37, -0.04) at 6 months (P=0.016), and -2.0 mmol/mol (-
4.1, 0.04) or -0.18% (-0.37, 0.004) at 12 months (P=0.055; Table 3). The primary outcome of 
the mean change in HbA1c between the two arms at 6 and 12 months was not significantly 
different. Non-inferiority would be established if the 95% two-sided CI for the difference 
between the 5-week and 1-week course was entirely above the non-inferiority margin (i.e. 
entirely above -0.5). For both the per-protocol and intent-to-treat analyses of the primary 
endpoint and the secondary outcome of change in HbA1c level from baseline to those at 6 
and 12 months for patients whose baseline HbA1c was >58 mmol/mol (>7.5%), the 95% CIs 
were within the non-inferiority margins (Table 4). The point estimate of the intracluster 
correlation for HbA1c between courses at 12 months was -0.02 (95% CI -0.10 to 0.12) which 
suggests little variation in outcome between courses and that the generalized estimated 
equations analysis would be similar to one which did not account for clustering. 
  
10 
 
Secondary outcomes 
 
Biomedical outcomes 
The number of episodes of severe hypoglycaemia was reduced in the 12 months after 
DAFNE training compared with the 12 months before. The estimated relative risk for after vs 
before DAFNE training was 0.18 (95% CI 0.03 to 0.936; P=0.042). This shows that patients 
have an 82% reduced risk of severe hypoglycaemia after vs before DAFNE training. The 
interaction between treatment arm for before vs after DAFNE training was not significant 
(P=0.939); thus, the decrease in risk was the same in both treatment arms. There were 
some small differences in other biomedical outcomes between the two arms. In the 5-week 
arm the mean (95% CI) decrease in weight was higher than in the 1-week arm [-1.61 kg (-
2.79, -0.44) vs -0.07 kg (-1.49, 1.35)] and was associated with bigger decreases in BMI [-0.54 
kg/m2 (-0.95, -0.14) vs 0.01 kg/m2 (-0.48, 0.50)], diastolic blood pressure [-2.7 mmHg (-5.6, 
0.2) vs 0.5 mmHg (-2.7, 3.6) mmHg] and triglycerides [-0.12 mmol/l (-0.31, 0.07) vs 0.30 
mmol/l (0.00, 0.65)] in the 5-week vs the 1-week arm. 
 
Psychosocial outcomes 
For all psychosocial outcomes, scores improved significantly 6 months after DAFNE training, 
the improvement was maintained at 12 months, and the 5-week intervention was non-
inferior to the 1-week intervention. For example, for the Problem Areas in Diabetes [15] 
questionnaire, which measures diabetes distress and in which lower scores indicate less 
distress, the mean score decreased from baseline by averages of 9.5 points at 6 months and 
10.2 points at 12 months, with no significant difference between the arms. Similar 
improvements were achieved and maintained across a range of other scales with no 
difference between treatment arms, i.e. the Hospital and Anxiety Depression scale [16], the 
Confidence in Diabetes Scale [17], the Diabetes-Specific Quality of Life (all subscales) [18], 
the Hypoglycaemia Fear Survey Worry Subscale [19], and the EuroQol questionnaire, the 
EQ-5D State of Health scale (Table 5) [20]. 
  
11 
 
Qualitative sub-study 
 
Some findings from the qualitative sub-study have been previously reported [8]; briefly, a 
comparison of 5-week and 1-ǁĞĞŬĐŽƵƌƐĞƉĂƌƚŝĐŝƉĂŶƚƐ ?ŝŶƚĞƌǀŝĞǁƐĚŝĚŶŽƚƐŚŽǁĂŶǇ
differences in their experiences and diabetes self-management practices after their courses. 
Positive experiences of the course were reported by both groups, with virtually all patients 
perceiving advantages to, and preferring the format of, the course that they had just 
attended. The 12-month follow-up questionnaire reinforced these findings, showing that 
85% of respondents thought that the format of course that they attended would be better 
than the alternative format. 
 
 
Discussion 
 
The results of this randomized controlled trial show that attending DAFNE structured 
training 1 day a week over 5 consecutive weeks is as effective as attending a standard 
DAFNE course delivered over 5 consecutive days. Although we only aimed to show that the 
5-week course was non-inferior to the 1-week course, we can conclude that the two formats 
are equivalent because the CIs for the difference are bounded by both -5.5 mmol/mol and 
+5.5mmol/mol (-0.5% and +0.5%). The mean change in HbA1c level from that at baseline vs 
those at 6 and 12 months was similar, and this was also true for patients with a baseline 
,ď ?ĐŽĨA? ? ?ŵŵŽů ?ŵŽů ?A? ? ? ?A?). Across the whole cohort, the relative risk of severe 
hypoglycaemia decreased by 82%, and this occurred independently of treatment arm. In the 
original DAFNE trial [1] no significant difference in the rate of severe hypoglycaemia was 
observed, but a reduction has been reported in a later observational study of an evaluated 
roll-out of DAFNE graduates [21], and in another report showing reductions in costs of 
emergency treatment after DAFNE training [22]. 
 
For the cohort as a whole, the improvement in HbA1c was modest; for those with baseline 
,ď ?ĐA? ? ? ŵŵŽů ?ŵŽů ?A? ? ? ?A? ? ?ŝƚǁĂƐ-2.2 mmol/mol (-0.2%) at 6 months (P=0.016) and -2.0 
mmol/mol (-0.18%) at 12 months (P=0.055). These values are greater than the change for 
the entire cohort, possibly because of regression to the mean; however, these changes were 
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smaller than those achieved in the original DAFNE trial, which reported a change in the 
group who received DAFNE of -11 mmol/mol (-1.0%) at 6 months, and -5.5 mmol/mol (-
0.5%) at 12 months [1]. The original DAFNE trial only recruited patients with an HbA1c level 
A? ? ?ŵŵŽů ?ŵŽů ?A? ?.5%) and so we can make a valid comparison. In the original DAFNE trial 
the mean HbA1c level for those who received the intervention was 79 mmol/mol (9.4%) 
which is greater than the level of 74 mmol/mol (9.0%) in the present restricted cohort, 
suggesting a greater possibility of regression to the mean in the original trial. However, 
HbA1c among the control group in the original trial went from 78 mmol/mol (9.3%) at 
baseline to 79 mol/mol (9.4%) after 6 months, which implies that we cannot attribute any of 
the change in the DAFNE group to regression to the mean. In addition, the success of the 
original DAFNE trial may have contributed to a change in culture so that more adults with 
Type 1 diabetes are now encouraged to use a basal-bolus regime (as opposed to a twice-
daily mix); and many patients now have some experience of carbohydrate counting even 
without formal DAFNE training [23]. The cohort in the present randomized controlled trial 
may therefore already have been more skilled in dose adjustment and carbohydrate 
counting, thus reducing the potential for improvement in HbA1c levels. It is noteworthy that 
another recent controlled trial of the DAFNE intervention also did not show much 
improvement in HbA1c [24], whilst observational data from two different cohorts have 
recently shown improvements in HbA1c of 3 mmol/mol (0.3%) at 12 months [22,25]. 
 
We also assessed psychosocial outcomes, confirming the findings of other DAFNE studies 
[21,24 ?26] by showing marked improvements at 6 months and maintenance at 12 months, 
with no differences between participants in the 5-week vs the 1-week arm. 
 
KŶĞŬĞǇŽďũĞĐƚŝǀĞŽĨƚŚĞƋƵĂůŝƚĂƚŝǀĞƌĞƐĞĂƌĐŚǁĂƐƚŽĂƐĐĞƌƚĂŝŶƉĂƚŝĞŶƚƐ ?ůŝŬĞƐĂŶĚĚŝƐůŝŬĞƐŽĨ
their courses and their views about which format should be offered in the future [8]. As 
reported elsewhere, before attending their courses, half the participants had no preference 
and those who did often cited logistical reasons for why one format would be better for 
them than the other [8]. After the course, however, participants overwhelmingly preferred 
the format they had just received, citing perceived educational, clinical and behavioural 
benefits to justify their post-course preferences [8]. While this raises important questions 
about the usefulness of patient consultation exercises, a subject debated in a separate 
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paper [8], these findings do suggest that both course formats are liked by participants. This 
is reflected by the fact that, once participants commenced a course, the number of drop-
outs was low (Fig. 1), with only one participant in the 1-week arm and seven participants in 
the 5-week arm dropping out. The reasons for drop-out were generally life events, for 
example, illness, bereavement, illness of a relative or snow, which are more likely to occur 
over a 5-week than a 1-week period. 
 
We have undertaken a detailed health economic analysis to compare the cost-effectiveness 
of the two different delivery formats of the course, the results of which are detailed in a 
separate paper [10], but indicate few differences. 
 
In conclusion, we have shown that there were no major differences in biomedical and 
psychosocial outcomes or in cost-effectiveness [10] between the 5-week and 1-week DAFNE 
courses. As participants valued both course formats highly, and some found it easier to 
attend one type than the other, we have been persuaded to provide both 5-week and 1-
week courses in the future. 
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FIGURE 1 CONSORT diagram: participant flow through the Dose Adjustment for Normal 
Eating 5×1-day randomized controlled trial. 
Assessed for eligibility 
(n=217) 
Excluded as did not meet 
inclusion criteria (n=4) 
Randomised         
(n=213) 
Allocated to 1 week 
course (n=101) 
Allocated to 5 week 
course (n=112) 
Attended 1 week 
baseline data collection 
(n=89) 
Attended 5 week 
baseline data collection 
(n=99) 
Failed to attend 
baseline (n=12) 
Failed to attend 
baseline (n=13) 
Dropped out prior 
to course (n= 6) 
Dropped out prior 
to course (n= 2) 
Commenced 1 week 
course (n=83) 
Commenced 5 week 
course (n=97) 
Excluded as 
HbA1c>12% (n= 1) 
Dropped out during 
course (n= 1) Missing 
baseline  HbA1c (n=1)  
Excluded as 
HbA1c>12% (n= 2) 
Dropped out during 
course (n= 7) 
Per protocol 1 week 
course (n=80) 
Per protocol 1 week 
course (n=88) 
Lost to follow-up 
(n=5) 
Lost to follow-up 
(n=3) 
1 week intervention 
analysed per protocol 
(n=75) 
5 week intervention 
analysed per protocol 
(n=85) 
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Table 1 Baseline summary statistics of participants 
 
 Treatment arm 
 
 1-week course (N = 80) 
 
5-week course (N = 88) 
Gender: male, n (%) 
 
39 (48.8) 56 (63.6) 
Ethnicity, n (%)   
White 77 (96.3) 83 (94.3) 
Other 3 (3.8) 5 (5.7) 
   
 
 
N Mean SD Min. Max. N Mean SD Min. Max. 
Age, years 
 
80 40.7 13.2 19.0 73.0 88 42.4 12.9 19.0 72.0 
Age at diagnosis, 
Years 
79 20.1 12.8 2.0 65.0 88 26.1 14.8 2.0 65.0 
Diabetes duration, 
Years 
79 20.9 13.7 0.0 51.0 88 16.3 12.0 0.0 48.0 
Weight, kg 
 
76 78.3 15.7 51.0 135.4 88 78.3 15.3 54.5 127.5 
Height, cm 
 
77 170.2 8.5 152.0 190.5 87 171.6 8.7 152.5 190.0 
BMI, kg/m² 
 
76 27.0 4.6 19.0 39.0 87 26.5 4.6 19.8 44.7 
Systolic blood 
pressure, mmHg 
76 132.0 18.7 103.0 224.0 86 127.4 18.2 90.0 198.0 
Diastolic blood 
pressure, mmHg 
71 75.3 9.8 55.0 100.0 86 74.0 10.2 44.0 100.0 
HbA1c 80     88     
mmol/mol  70.3 1.1 46 101  67.5 14.8 33 102 
% 
 
 8.59 1.97 6.4 11.4  8.33 1.35 5.2 11.5 
Total cholesterol, 
mmol/l 
76 4.6 0.9 2.8 7.7 84 4.3 0.7 2.5 6.5 
Triglycerides, 
mmol/l 
55 1.2 0.6 0.4 3.4 66 1.3 1.0 0.4 5.5 
HDL, mmol/l 
 
65 1.6 0.5 0.6 3.2 80 1.5 0.4 0.8 2.9 
eGFR<60 
ml/min/1.73m², n(%) 
5 (6.3) 1 (1.1) 
eGFR>60 
ml/min/1.73m², n(%) 
71 (88.8) 73 (83.0) 
 
eGFR, estimated glomerular filtration rate 
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Table 2 Baseline summary statistics of psychosocial measures 
Questionnaire Treatment Arm 
1-week course 5-week course 
N Mean SD Min. Max. N Mean SD Min. Max. 
Problem Areas in 
Diabetes 
 
80 27.44 20.39 1.25 82.50 85 27.82 20.05 1.24 100.00 
Hospital and 
Anxiety 
Depression 
Scale: Anxiety 
80 6.86 4.11 0.00 18.00 85 7.08 4.08 0.00 18.00 
 
Hospital and 
Anxiety 
Depression 
Scale: 
Depression 
80 4.05 3.56 0.00 14.00 85 4.46 3.44 0.00 18.00 
Confidence in 
Diabetes Score 
 
69 82.29 10.47 47.00 100.00 84 82.67 10.90 54.00 100.00 
Diabetes-Specific 
Quality of Life, 
total 
80 31.45 19.05 1.05 91.93 85 30.40 17.28 0.00 98.60 
Hypoglycaemia 
Fear Survey 
Worry Score 
73 28.51 8.66 13.00 49.00 87 30.25 12.78 13.00 65.00 
EQ-5D, single 
index 
 
79 85.12 23.62 -1.60 100.00 79 82.34 23.58 12.40 100.00 
EQ-5D, State of 
Health 
 
80 69.93 16.58 22.00 99.00 84 69.81 18.67 20.00 100.00 
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Table 3 Mean change in HbA1c level across the entire 5x1 cohort 
 N Unadjusted mean change 95% CI P 
HbA1c level 
 
    
6 months 
 
166   0.277 
mmol/mol 
 
 -0.8 (69.4 to 68.5) -2.3, 0.7  
% 
 
 -0.08 (8.50 to 8.42) -0.21, 0.06  
12 months 
 
167   0.382 
mmol/mol 
 
 -0.7 (68.9 to 68.2) -2.4, 0.9  
% 
 
 -0.07 (8.46 to 8.39) -0.22, 0.08  
Baseline HBA1c ш 58 
mmol/mol (7.5%) 
    
6 months 
 
127   0.016 
mmol/mol 
 
 -2.2 (74.7 to 72.5) -4.0, -0.4  
% 
 
 -0.20 (8.99 to 8.78) -0.37 to -0.04  
12 months 
 
126   0.055 
mmol/mol 
 
 -2.0 (74.4 to 72.4) -4.1, 0.04  
% 
 
 -0.18 (8.96 to 8.78) -0.37, 0.004  
 
  
23 
 
Table 4 Per-protocol and intent-to-treat analysis of change in HbA1c level 
 1-week course 5-week course  
 N Mean  
changeΏ 
(95% CI) 
N Mean  
changeΏ 
(95% CI) 
Model summary 
coefficient* 
(95% CI) 
Per-protocol analysis 
 
     
Whole Population 
 
     
6 months 
 
70  84   
mmol/mol 
 
 -1.0 (-3.3, 1.3)  -0.9 (-3.0, 1.3) 0.4 (-2.4, 3.1) 
% 
 
 -0.09 (-0.30, 0.12)  -0.08 (-0.27, 0.11) 0.03 (-0.22, 0.28) 
12 months 
 
72  84   
mmol/mol 
 
 -1.5 (-4.1, 1.1)  0.0 (-2.4, 2.4) -0.9 (-3.9, 2.2) 
% 
 
 -0.14 (-0.37, 0.10)  0.00 (-0.22, 0.22) -0.08 (-0.36, 0.20) 
Baseline HBA1c ш 58 
mmol/mol (7.5%) 
     
6 months 
 
59  58   
mmol/mol 
 
 -1.8 (-4.4, 0.9)  -2.7 (-5.4, 0.03) 0.4 (-2.6, 3.4) 
% 
 
 -0.16 (-0.41, 0.08)  -0.25 (-0.50, 0.00) 0.04 (-0.24, 0.31) 
12 months 
 
61  56   
mmol/mol 
 
 -2.3 (-5.2, 0.7)  -1.6 (-4.9, 1.7) -1.2 (-5.0, 2.7) 
% 
 
 -0.21 (-0.48, 0.06)  -0.14 (-0.44, 0.16) -0.11 (-0.46, 0.25) 
Intent-to-treat  
analysis 
     
Whole Population 
 
     
6 months 
 
75  91   
mmol/mol 
 
 -1.0 (-3.2, 1.2)  -0.7 (-2.8, 1.4) 0.4 (-2.2, 3.0) 
% 
 
 
 -0.09 (-0.20, 0.11)  -0.07 (-0.26, 0.13) 0.03 (-0.21, 0.27) 
24 
 
12 months 
 
77  90   
mmol/mol 
 
 -1.8 (-4.2, 0.7)  0.2 (-2.1, 2.4) -1.4 (-4.2, 1.4) 
% 
 
 -0.16 (-0.38, 0.06)  0.01 (-0.19, 0.22) -0.13 (-0.39, 0.13) 
Baseline HBA1c ш 58 
mmol/mol (7.5%) 
     
6 months 
 
64  63   
mmol/mol 
 
 -1.7 (-4.2, 0.8)  -2.7 (-5.4, -0.1) 0.7 (-2.1, 3.5) 
% 
 
 -0.15 (-0.38, 0.07)  -0.25 (-0.50, -0.01) 0.06 (-0.19, 0.32) 
12 months 
 
66  60   
mmol/mol 
 
 -2.5 (-5.3, 0.2)  -1.4 (-4.6, 1.7) -1.6 (-5.2, 2.1) 
% 
 
 -0.23 (-0.48, 0.02)  -0.13 (-0.42, 0.16) -0.14 (0.47, 0.19) 
 
 ? Unadjusted mean change 
* Difference between treatment groups, adjusted for baseline value and cluster effect. A 
positive value indicates that the 5-week course has a better change. Non-inferiority is 
established if the 95% two-sided CI for the difference between the 5-week course and 1-
week course is entirely above the non-inferiority margin (i.e. entirely above -0.5). 
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Table 5 Psychosocial outcomes 
Questionnaire  1-week course 5-week course  
 Months 
post 
course 
N Mean  
changeΏ 
(95% CI) 
N Mean  
changeΏ 
(95% CI) 
Model summary 
coefficient* 
(95% CI) 
Problem Areas  
in Diabetes 
6 63 -10.04 
(-14.41, -5.66) 
72 -9.11 
(-12.11, -6.11) 
-2.21 
(-7.27, 2.86) 
 12 
 
62 -8.78 
(-13.30, -4.27) 
74 -11.30 
(-14.30, -8.30) 
3.18 
(-1.31, 7.66) 
Hospital and Anxiety 
Depression scale: 
6 63 -0.65 
(-1.38, 0.08) 
71 -0.86 
(-1.58, -0.14) 
0.08 
(-0.96, 1.12) 
anxiety 
 
12 62 -1.11 
(-1.98, -0.24) 
75 -1.88 
(-2.75, -1.02) 
0.71 
(-0.44, 1.85) 
Hospital and Anxiety 
Depression scale: 
6 63 -0.87 
(-1.61, -0.13) 
71 -0.88 
(-1.34, -0.43) 
-0.10 
(-1.05, 0.86) 
depression 12 62 -0.93 
(-1.66, -0.20) 
74 -1.23 
(-1.85, -0.60) 
0.15 
(-0.71, 1.01) 
Confidence in  
Diabetes Scale 
6 56 7.36 
(4.50, 10.22) 
71 5.41 
(3.31, 7.51) 
-1.11 
(-3.60, 1.39) 
 12 54 5.16 
(2.13, 8.19) 
73 5.66 
(3.45, 7.87) 
0.88 
(-1.98, 3.75) 
Diabetes-Specific 
Quality of Life, 
6 63 -10.07 
(-14.09, -6.04) 
72 -8.24 
(-10.97, -5.52) 
-2.04 
(-6.13, -2.06) 
total 12 62 -10.75 
(-14.44, -7.06) 
75 -10.45 
(-13.34, -7.57) 
0.27 
(-3.42, 3.96) 
Hypoglycaemia Fear 
Survey Worry Score 
6 58 -0.80 
(-2.35, 0.75) 
73 -3.50 
(-5.71, -1.29) 
2.01 
(0.59, 3.43) 
 12 56 -2.63 
(-4.92, -0.33) 
76 -4.01 
(-6.39, -1.63) 
0.33 
(-2.21, 2.86) 
EQ-5D, single index 6 61 0.47 
(-3.20, 4.14) 
64 4.25 
(-0.58, 9.09) 
2.59 
(-3.51, 8.69) 
 12 61 -0.91 
(-3.84, 2.02) 
69 3.26 
(-0.60, 7.12) 
3.66 
(-1.09, 8.41) 
EQ-5D, State  
of Health 
6 62 5.26 
(0.85, 9.97) 
71 5.08 
(0.82, 9.35) 
0.33 
(-4.90, 5.56) 
 12 62 4.40 
(0.18, 8.63) 
74 6.20 
(2.28, 10.13) 
2.64 
(-1.75, 7.02) 
 ? Unadjusted mean change 
* Difference between treatment groups, adjusted for baseline value and cluster effect. A 
positive value indicates that the 5-week course has a better change, all 95% Cis include zero, 
so the outcomes of the 5-week course are not significantly different from the outcomes of 
the 1-week course. 
 
